Scott D.  Sandell net worth and biography

Scott Sandell Biography and Net Worth

Major Shareholder of Ardelyx
Scott D. Sandell is an Independent Director of the Company. Mr. Sandell is Managing General Partner at global venture capital firm New Enterprise Associates, Inc. (“NEA”). As a General Partner since 2000 and Co-Managing General Partner from 2015 to 2017, Mr. Sandell served as head of the firm’s technology investing practice for 10 years and has led NEA’s China investing activities for over a decade. Prior to joining NEA in 1996, Mr. Sandell worked as a Product Manager for Windows 95 at Microsoft Corporation. Mr. Sandell started his career at the Boston Consulting Group, a global management consulting firm, and later joined C-ATS Software, Inc., a software development company. Mr. Sandell currently serves on the boards of various private companies. He previously served on the boards of, among others, Data Domain, Inc., Fusion-io, Inc., Neoteris, Inc., NetIQ Corporation, Playdom, Inc., Spreadtrum Communications, Inc., Tableau Software Inc., WebEx Communications, Inc., and Workday, Inc. Mr. Sandell also currently serves on the Board of Advisors for the Thayer School of Engineering at Dartmouth and is a former Chairman of the National Venture Capital Association, a trade organization for venture capital and private equity firms. Mr. Sandell holds an A.B. from Dartmouth College and an M.B.A. from Stanford University.

What is Scott D. Sandell's net worth?

The estimated net worth of Scott D. Sandell is at least $39,910.75 as of November 20th, 2023. Mr. Sandell owns 6,325 shares of Ardelyx stock worth more than $39,911 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Sandell may own. Learn More about Scott D. Sandell's net worth.

How do I contact Scott D. Sandell?

The corporate mailing address for Mr. Sandell and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Scott D. Sandell's contact information.

Has Scott D. Sandell been buying or selling shares of Ardelyx?

Scott D. Sandell has not been actively trading shares of Ardelyx during the last ninety days. Most recently, Scott D. Sandell sold 1,000,735 shares of the business's stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $1.24, for a transaction totalling $1,240,911.40. Learn More on Scott D. Sandell's trading history.

Who are Ardelyx's active insiders?

Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.

Are insiders buying or selling shares of Ardelyx?

In the last year, insiders at the biopharmaceutical company sold shares 31 times. They sold a total of 643,508 shares worth more than $3,874,269.01. The most recent insider tranaction occured on April, 15th when CEO Michael Raab sold 7,500 shares worth more than $52,950.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.

Information on this page was last updated on 4/15/2024.

Scott D. Sandell Insider Trading History at Ardelyx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2021Sell1,000,735$1.24$1,240,911.40View SEC Filing Icon  
12/9/2021Sell669,483$1.51$1,010,919.33View SEC Filing Icon  
6/15/2020Sell43$6.37$273.91View SEC Filing Icon  
11/12/2018Sell592$2.98$1,764.16View SEC Filing Icon  
12/26/2014Sell1,972$21.28$41,964.16View SEC Filing Icon  
See Full Table

Scott D. Sandell Buying and Selling Activity at Ardelyx

This chart shows Scott D Sandell's buying and selling at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ardelyx Company Overview

Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $6.31
Low: $6.23
High: $6.45

50 Day Range

MA: $7.90
Low: $6.31
High: $9.67

2 Week Range

Now: $6.31
Low: $3.16
High: $10.13

Volume

5,171,390 shs

Average Volume

6,063,456 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85